GrippeAllemagneV3, Main, Exploration, bibRecord, 000247

H1N1v at a seroepidemiological glance: is the nightmare over?

Identifieur interne : 000247 ( Main/Exploration ); précédent : 000246; suivant : 000248

H1N1v at a seroepidemiological glance: is the nightmare over?

Auteurs : C. Reinheimer [Allemagne] ; H W Doerr ; I. Friedrichs ; M. Stürmer ; R. Allwinn

Source :

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology [ 1435-4373 ] ; 2012.

RBID : pubmed:22065279

Descripteurs français

KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Allemagne (épidémiologie), Anticorps antiviraux (sang), Enfant, Enfant d'âge préscolaire, Femelle, Grippe humaine (immunologie), Grippe humaine (virologie), Grippe humaine (épidémiologie), Humains, Immunité de groupe, Jeune adulte, Mâle, Nourrisson, Sous-type H1N1 du virus de la grippe A (), Sous-type H1N1 du virus de la grippe A (immunologie), Sous-type H1N1 du virus de la grippe A (isolement et purification), Sujet âgé, Sujet âgé de 80 ans ou plus, Tests d'inhibition de l'hémagglutination, Études séroépidémiologiques.
MESH :
- immunologie : Grippe humaine, Sous-type H1N1 du virus de la grippe A.
- isolement et purification : Sous-type H1N1 du virus de la grippe A.
- sang : Anticorps antiviraux.
- virologie : Grippe humaine.
- épidémiologie : Allemagne, Grippe humaine.
- Adolescent, Adulte, Adulte d'âge moyen, Enfant, Enfant d'âge préscolaire, Femelle, Humains, Immunité de groupe, Jeune adulte, Mâle, Nourrisson, Sous-type H1N1 du virus de la grippe A, Sujet âgé, Sujet âgé de 80 ans ou plus, Tests d'inhibition de l'hémagglutination, Études séroépidémiologiques.
Wicri :
- geographic : Allemagne.

English descriptors

KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral (blood), Child, Child, Preschool, Female, Germany (epidemiology), Hemagglutination Inhibition Tests, Humans, Immunity, Herd, Infant, Influenza A Virus, H1N1 Subtype (classification), Influenza A Virus, H1N1 Subtype (immunology), Influenza A Virus, H1N1 Subtype (isolation & purification), Influenza, Human (epidemiology), Influenza, Human (immunology), Influenza, Human (virology), Male, Middle Aged, Seroepidemiologic Studies, Young Adult.
MESH :
- chemical , blood : Antibodies, Viral.
- geographic , epidemiology : Germany.
- classification : Influenza A Virus, H1N1 Subtype.
- epidemiology : Influenza, Human.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza, Human.
- isolation & purification : Influenza A Virus, H1N1 Subtype.
- virology : Influenza, Human.
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Hemagglutination Inhibition Tests, Humans, Immunity, Herd, Infant, Male, Middle Aged, Seroepidemiologic Studies, Young Adult.

Abstract

When the second wave of pandemic influenza A H1N1v 2009 (H1N1v) emerged in the winter of 2010/2011, public health authorities were afraid of dangerous implications and severe clinical courses again. As further H1N1v waves might appear, achievement of sufficient herd immunity is a matter of urgency. The objective of this study was to determine the seroprevalence of antibodies against H1N1v by hemagglutination-inhibition test (HI) after the second wave. We compared our recent findings with our data obtained after the first pandemic in 2009/2010. Between March and May 2011 we collected serum samples from 600 persons aged 1 to 84 years admitted to University Hospital Frankfurt/Main and analysed the titres of anti-H1N1v by HI. The overall seroprevalence of anti-H1N1v has risen from 36.9% (95% confidence interval (95%CI), 33-41) in unvaccinated persons after the first wave to 57.3% (95%CI, 53.1-61.2) in vaccinated and unvaccinated. The highest rate of seropositivity was detected in the age group of 10-19 years (66%; 95%CI, 55.8-75.2), whereas the lowest was found in the age group 40-59 years (51%; 95%CI, 40.8-61.1). Although seroprevalence has significantly increased, sufficient herd immunity is still not achieved. Therefore, general vaccination programs have to be propagated continuously by public health authorities.

DOI: 10.1007/s10096-011-1465-x
PubMed: 22065279

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000258
to stream Main, to step Curation: 000258

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">H1N1v at a seroepidemiological glance: is the nightmare over?</title>
<author><name sortKey="Reinheimer, C" sort="Reinheimer, C" uniqKey="Reinheimer C" first="C" last="Reinheimer">C. Reinheimer</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute for Medical Virology, University Hospital Frankfurt am Main, Paul-Ehrlich-Straße 40, 60596, Frankfurt am Main, Germany. claudia.reinheimer@kgu.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Medical Virology, University Hospital Frankfurt am Main, Paul-Ehrlich-Straße 40, 60596, Frankfurt am Main</wicri:regionArea>
<placeName><region type="land" nuts="1">Hesse (Land)</region>
<region type="district" nuts="2">District de Darmstadt</region>
<settlement type="city">Francfort-sur-le-Main</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Doerr, H W" sort="Doerr, H W" uniqKey="Doerr H" first="H W" last="Doerr">H W Doerr</name>
</author>
<author><name sortKey="Friedrichs, I" sort="Friedrichs, I" uniqKey="Friedrichs I" first="I" last="Friedrichs">I. Friedrichs</name>
</author>
<author><name sortKey="Sturmer, M" sort="Sturmer, M" uniqKey="Sturmer M" first="M" last="Stürmer">M. Stürmer</name>
</author>
<author><name sortKey="Allwinn, R" sort="Allwinn, R" uniqKey="Allwinn R" first="R" last="Allwinn">R. Allwinn</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22065279</idno>
<idno type="pmid">22065279</idno>
<idno type="doi">10.1007/s10096-011-1465-x</idno>
<idno type="wicri:Area/Main/Corpus">000258</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000258</idno>
<idno type="wicri:Area/Main/Curation">000258</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000258</idno>
<idno type="wicri:Area/Main/Exploration">000258</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">H1N1v at a seroepidemiological glance: is the nightmare over?</title>
<author><name sortKey="Reinheimer, C" sort="Reinheimer, C" uniqKey="Reinheimer C" first="C" last="Reinheimer">C. Reinheimer</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute for Medical Virology, University Hospital Frankfurt am Main, Paul-Ehrlich-Straße 40, 60596, Frankfurt am Main, Germany. claudia.reinheimer@kgu.de</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Medical Virology, University Hospital Frankfurt am Main, Paul-Ehrlich-Straße 40, 60596, Frankfurt am Main</wicri:regionArea>
<placeName><region type="land" nuts="1">Hesse (Land)</region>
<region type="district" nuts="2">District de Darmstadt</region>
<settlement type="city">Francfort-sur-le-Main</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Doerr, H W" sort="Doerr, H W" uniqKey="Doerr H" first="H W" last="Doerr">H W Doerr</name>
</author>
<author><name sortKey="Friedrichs, I" sort="Friedrichs, I" uniqKey="Friedrichs I" first="I" last="Friedrichs">I. Friedrichs</name>
</author>
<author><name sortKey="Sturmer, M" sort="Sturmer, M" uniqKey="Sturmer M" first="M" last="Stürmer">M. Stürmer</name>
</author>
<author><name sortKey="Allwinn, R" sort="Allwinn, R" uniqKey="Allwinn R" first="R" last="Allwinn">R. Allwinn</name>
</author>
</analytic>
<series><title level="j">European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology</title>
<idno type="eISSN">1435-4373</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antibodies, Viral (blood)</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Female</term>
<term>Germany (epidemiology)</term>
<term>Hemagglutination Inhibition Tests</term>
<term>Humans</term>
<term>Immunity, Herd</term>
<term>Infant</term>
<term>Influenza A Virus, H1N1 Subtype (classification)</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza A Virus, H1N1 Subtype (isolation & purification)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (immunology)</term>
<term>Influenza, Human (virology)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Seroepidemiologic Studies</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Allemagne (épidémiologie)</term>
<term>Anticorps antiviraux (sang)</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Femelle</term>
<term>Grippe humaine (immunologie)</term>
<term>Grippe humaine (virologie)</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Humains</term>
<term>Immunité de groupe</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Nourrisson</term>
<term>Sous-type H1N1 du virus de la grippe A ()</term>
<term>Sous-type H1N1 du virus de la grippe A (immunologie)</term>
<term>Sous-type H1N1 du virus de la grippe A (isolement et purification)</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Tests d'inhibition de l'hémagglutination</term>
<term>Études séroépidémiologiques</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Germany</term>
</keywords>
<keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Grippe humaine</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Allemagne</term>
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Female</term>
<term>Hemagglutination Inhibition Tests</term>
<term>Humans</term>
<term>Immunity, Herd</term>
<term>Infant</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Seroepidemiologic Studies</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Femelle</term>
<term>Humains</term>
<term>Immunité de groupe</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Nourrisson</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Tests d'inhibition de l'hémagglutination</term>
<term>Études séroépidémiologiques</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">When the second wave of pandemic influenza A H1N1v 2009 (H1N1v) emerged in the winter of 2010/2011, public health authorities were afraid of dangerous implications and severe clinical courses again. As further H1N1v waves might appear, achievement of sufficient herd immunity is a matter of urgency. The objective of this study was to determine the seroprevalence of antibodies against H1N1v by hemagglutination-inhibition test (HI) after the second wave. We compared our recent findings with our data obtained after the first pandemic in 2009/2010. Between March and May 2011 we collected serum samples from 600 persons aged 1 to 84 years admitted to University Hospital Frankfurt/Main and analysed the titres of anti-H1N1v by HI. The overall seroprevalence of anti-H1N1v has risen from 36.9% (95% confidence interval (95%CI), 33-41) in unvaccinated persons after the first wave to 57.3% (95%CI, 53.1-61.2) in vaccinated and unvaccinated. The highest rate of seropositivity was detected in the age group of 10-19 years (66%; 95%CI, 55.8-75.2), whereas the lowest was found in the age group 40-59 years (51%; 95%CI, 40.8-61.1). Although seroprevalence has significantly increased, sufficient herd immunity is still not achieved. Therefore, general vaccination programs have to be propagated continuously by public health authorities.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22065279</PMID>
<DateCompleted><Year>2012</Year>
<Month>08</Month>
<Day>30</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>03</Month>
<Day>05</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1435-4373</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>31</Volume>
<Issue>7</Issue>
<PubDate><Year>2012</Year>
<Month>Jul</Month>
</PubDate>
</JournalIssue>
<Title>European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology</Title>
<ISOAbbreviation>Eur. J. Clin. Microbiol. Infect. Dis.</ISOAbbreviation>
</Journal>
<ArticleTitle>H1N1v at a seroepidemiological glance: is the nightmare over?</ArticleTitle>
<Pagination><MedlinePgn>1467-71</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s10096-011-1465-x</ELocationID>
<Abstract><AbstractText>When the second wave of pandemic influenza A H1N1v 2009 (H1N1v) emerged in the winter of 2010/2011, public health authorities were afraid of dangerous implications and severe clinical courses again. As further H1N1v waves might appear, achievement of sufficient herd immunity is a matter of urgency. The objective of this study was to determine the seroprevalence of antibodies against H1N1v by hemagglutination-inhibition test (HI) after the second wave. We compared our recent findings with our data obtained after the first pandemic in 2009/2010. Between March and May 2011 we collected serum samples from 600 persons aged 1 to 84 years admitted to University Hospital Frankfurt/Main and analysed the titres of anti-H1N1v by HI. The overall seroprevalence of anti-H1N1v has risen from 36.9% (95% confidence interval (95%CI), 33-41) in unvaccinated persons after the first wave to 57.3% (95%CI, 53.1-61.2) in vaccinated and unvaccinated. The highest rate of seropositivity was detected in the age group of 10-19 years (66%; 95%CI, 55.8-75.2), whereas the lowest was found in the age group 40-59 years (51%; 95%CI, 40.8-61.1). Although seroprevalence has significantly increased, sufficient herd immunity is still not achieved. Therefore, general vaccination programs have to be propagated continuously by public health authorities.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reinheimer</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Institute for Medical Virology, University Hospital Frankfurt am Main, Paul-Ehrlich-Straße 40, 60596, Frankfurt am Main, Germany. claudia.reinheimer@kgu.de</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Doerr</LastName>
<ForeName>H W</ForeName>
<Initials>HW</Initials>
</Author>
<Author ValidYN="Y"><LastName>Friedrichs</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y"><LastName>Stürmer</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Allwinn</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2011</Year>
<Month>11</Month>
<Day>09</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>Eur J Clin Microbiol Infect Dis</MedlineTA>
<NlmUniqueID>8804297</NlmUniqueID>
<ISSNLinking>0934-9723</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006385" MajorTopicYN="N">Hemagglutination Inhibition Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D032521" MajorTopicYN="N">Immunity, Herd</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year>
<Month>06</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2011</Year>
<Month>10</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2011</Year>
<Month>11</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2011</Year>
<Month>11</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2012</Year>
<Month>8</Month>
<Day>31</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">22065279</ArticleId>
<ArticleId IdType="doi">10.1007/s10096-011-1465-x</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Clin Vaccine Immunol. 2011 May;18(5):860-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21346056</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2010 Mar 27;375(9720):1100-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20096450</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2009 Nov 12;361(20):1945-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19745214</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2011 Feb 23;6(2):e17074</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21373639</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2010 Nov 11;15(45):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21087590</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infection. 2011 Apr;39(2):101-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21424756</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2011 May 19;16(20):19871</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21616049</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>CMAJ. 2010 Oct 5;182(14):1522-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20823167</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2011 Jun;49(6):2210-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21471339</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Microbiol Infect Dis. 2010 Nov;29(11):1327-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20623384</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care Med. 2010 Apr;38(4 Suppl):e1-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20029350</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2010 Oct 07;15(40):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20946757</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Microbiol Infect Dis. 2011 Oct;30(10):1201-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21442359</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2010 Jul 29;15(30):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20684814</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Curr. 2010 Feb 24;2:RRN1148</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20191082</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010 Jul 14;5(7):e11601</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20644650</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infection. 2009 Oct;37(5):381-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19768379</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Epidemiol. 2011 Mar;26(3):211-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21476080</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Public Health. 2011 Mar 04;11:149</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21375758</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vet Ital. 2010 Apr-Jun;46(2):147-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20560124</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Public Health. 2011 Mar 08;11:152</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21385436</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Chin Med Assoc. 2010 Feb;73(2):62-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20171584</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2009 Dec 03;4(12):e8032</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19997505</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Microbiol Immunol. 2009 Aug;198(3):175-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19543913</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Health Popul Nutr. 2010 Dec;28(6):537-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21261198</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2010 Aug 25;10:255</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20738878</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Iran J Immunol. 2010 Mar;7(1):39-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20371918</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Microbiol Immunol. 2010 May;199(2):117-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20162304</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
</country>
<region><li>District de Darmstadt</li>
<li>Hesse (Land)</li>
</region>
<settlement><li>Francfort-sur-le-Main</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Allwinn, R" sort="Allwinn, R" uniqKey="Allwinn R" first="R" last="Allwinn">R. Allwinn</name>
<name sortKey="Doerr, H W" sort="Doerr, H W" uniqKey="Doerr H" first="H W" last="Doerr">H W Doerr</name>
<name sortKey="Friedrichs, I" sort="Friedrichs, I" uniqKey="Friedrichs I" first="I" last="Friedrichs">I. Friedrichs</name>
<name sortKey="Sturmer, M" sort="Sturmer, M" uniqKey="Sturmer M" first="M" last="Stürmer">M. Stürmer</name>
</noCountry>
<country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Reinheimer, C" sort="Reinheimer, C" uniqKey="Reinheimer C" first="C" last="Reinheimer">C. Reinheimer</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeAllemagneV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000247 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000247 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    GrippeAllemagneV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:22065279
   |texte=   H1N1v at a seroepidemiological glance: is the nightmare over?
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:22065279" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeAllemagneV3

This area was generated with Dilib version V0.6.35.
Data generation: Tue Jul 7 11:47:10 2020. Site generation: Sat Sep 26 09:55:33 2020

	Corpus GrippeAllemagneV3
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Corpus GrippeAllemagneV3

H1N1v at a seroepidemiological glance: is the nightmare over?

H1N1v at a seroepidemiological glance: is the nightmare over?

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki